Insider Selling: Natera (NASDAQ:NTRA) CEO Sells $919,184.00 in Stock

Key Points

• Natera CEO Steven Chapman sold 2,264 shares for $919,184 under a pre-arranged Rule 10b5-1 plan to cover tax withholding on vested equity awards, reducing his direct holdings by 2.34% to 94,662 shares.
• Natera’s stock recently traded at $436, near its 52-week high of $437.41, after strong quarterly results that included revenue growth of 37.7% year over year and an EPS loss narrower than analysts expected.
• Analysts remain broadly bullish, with a consensus “Moderate Buy” rating and an average price target of $394.31, while investors await third-quarter 2026 results on November 5 amid expectations for continued Signatera growth and potential earnings volatility.

Natera, Inc. (NASDAQ:NTRA - Get Free Report) CEO Steven Chapman sold 2,264 shares of Natera stock in a transaction that occurred on Tuesday, October 27th. The stock was sold at an average price of $406.00, for a total transaction of $919,184.00. Following the transaction, the chief executive officer directly owned 94,662 shares in the company, valued at $38,432,772. The trade was a 2.34% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Steven Leonard Chapman also recently made the following trade(s):

• On Wednesday, October 28th, Steven Chapman sold 3,430 shares of Natera stock. The shares were sold at an average price of $426.34, for a total transaction of $1,462,346.20.
• On Thursday, October 1st, Steven Chapman sold 1,273 shares of Natera stock. The stock was sold at an average price of $413.31, for a total transaction of $526,143.63.
• On Tuesday, September 1st, Steven Chapman sold 1,698 shares of Natera stock. The stock was sold at an average price of $320.99, for a total transaction of $545,041.02.
• On Monday, August 3rd, Steven Chapman sold 3,076 shares of Natera stock. The shares were sold at an average price of $266.39, for a total transaction of $819,415.64.

Natera Price Performance

Shares of NTRA traded up $11.58 during trading hours on Thursday, reaching $436.00. The stock had a trading volume of 1,325,469 shares, compared to its average volume of 1,585,948. Natera, Inc. has a 52 week low of $181.00 and a 52 week high of $437.41. The firm has a 50-day moving average of $375.27 and a 200 day moving average of $265.54.

Natera (NASDAQ:NTRA - Get Free Report) last posted its earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.49) by $0.02. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%. The firm had revenue of $752.75 million during the quarter, compared to analysts' expectations of $661.24 million. During the same period in the previous year, the firm earned ($0.74) earnings per share. The company's revenue was up 37.7% on a year-over-year basis. On average, research analysts expect that Natera, Inc. will post -1.14 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on NTRA. Citigroup boosted their price target on Natera from $365.00 to $480.00 and gave the company a "buy" rating in a report on Tuesday, October 6th. JPMorgan Chase & Co. upped their price target on Natera from $360.00 to $460.00 and gave the stock an "overweight" rating in a research report on Wednesday, October 14th. Roth Capital initiated coverage on shares of Natera in a research report on Thursday, October 22nd. They issued a "buy" rating and a $475.00 price objective on the stock. TD Cowen increased their target price on shares of Natera from $340.00 to $480.00 and gave the stock a "buy" rating in a report on Tuesday, October 13th. Finally, Robert W. Baird set a $348.00 target price on shares of Natera in a research report on Friday, August 7th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, two have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Natera has a consensus rating of "Moderate Buy" and an average target price of $394.31.

Key Headlines Impacting Natera

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera presented 25 abstracts at the ESMO oncology conference, highlighting additional Signatera data and supporting the test’s potential commercial and clinical adoption. Natera presents 25 ESMO abstracts
• Positive Sentiment: Investors reacted favorably to Signatera clinical and regulatory wins, which could strengthen Natera’s competitive position in minimal residual disease testing and support future revenue growth. Investors React to Signatera Wins
• Positive Sentiment: The third-quarter outlook centers on continued Signatera volume growth, higher test prices, regulatory progress and expanding Medicare coverage that could benefit Natera’s organ-health business. NTRA Q3 Earnings Preview
• Neutral Sentiment: Natera will release third-quarter 2026 results on November 5 after the market closes, giving investors a near-term catalyst to assess testing volumes, reimbursement trends and profitability. Natera Q3 Results Announcement
• Negative Sentiment: Zacks cautions that Natera may report negative earnings and lacks the typical combination of estimate revisions and momentum associated with a likely earnings beat, raising the risk of volatility around the report. Natera Earnings Beat Outlook
• Negative Sentiment: One valuation analysis estimates NTRA could be about 32% below fair value based on ESMO-related data, suggesting the stock’s gains may have outpaced its fundamentals. Natera Fair Value Analysis
• Negative Sentiment: Two company officers disclosed plans to sell a combined 1,768 shares, including 771 shares valued at approximately $312,000; the transactions are relatively small but may modestly weigh on sentiment. John Fesko Share Sale Solomon Moshkevich Share Sale

Hedge Funds Weigh In On Natera

Several large investors have recently modified their holdings of NTRA. Greenleaf Trust bought a new stake in Natera in the 3rd quarter valued at $240,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Natera in the third quarter valued at approximately $7,545,000. Profund Advisors LLC grew its position in Natera by 5.6% during the third quarter. Profund Advisors LLC now owns 6,553 shares of the medical research company's stock worth $2,708,000 after buying an additional 348 shares in the last quarter. Vise Technologies Inc. increased its stake in Natera by 5.3% during the 3rd quarter. Vise Technologies Inc. now owns 2,010 shares of the medical research company's stock worth $831,000 after acquiring an additional 101 shares during the period. Finally, Americana Partners LLC acquired a new position in Natera in the 3rd quarter valued at $203,000. 99.90% of the stock is owned by institutional investors.

Natera Company Profile

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals.

In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.